84 results about "Ischemic Heart Diseases" patented technology

The invention discloses application of an RNF130 activator in preparation of a medicine for preventing and / or treating ischemic heart disease, and belongs to the technical field of biological medicine. Research results show that when an RNF130 activator is given in a mouse of a myocardial ischemia reperfusion injury model, the left ventricular ejection fraction and the left ventricular short-axis shortening rate of the mouse can be improved, myocardial tissue pathological injury can be relieved, the protein expression levels of NOX-2, BAX and TNF-alpha are reduced, the myocardial infarction area is reduced, and myocardial cell apoptosis is reduced; therefore, the RNF130 activator has prevention and treatment effects on the myocardial ischemia-reperfusion injury, that is, the RNF130 activator can be used as an effective component of the medicine for preventing or treating diabetes complicated by myocardial ischemia-reperfusion injury, and a new strategy is provided for preparation of the medicine for preventing and treating myocardial ischemia-reperfusion injury.

The invention relates to lauroyl cilostazol as well as a preparation method and application thereof. Wherein the lauroyl cilostazol is sterile, and preferably, the lauroyl cilostazol is a crystal. The invention further provides application of the lauroyl cilostazol in preparing medicines for treating cerebral infarction, cerebrovascular diseases, atherosclerosis, diabetic complications, peripheral vascular diseases, Reynolds diseases, intermittent claudication, ischemic heart diseases and acute coronary syndromes. The lauroyl cilostazol has the remarkable long-acting characteristic.

The invention discloses application of chrysin-7-0-beta-D-glucuronide in treatment of ischemic heart disease or an LRP6 inhibitor, and belongs to the technical field of treatment of ischemic heart disease. The invention provides a new application of a small molecular compound chrysin-7-0-beta-D-glucuronide, the compound realizes regulation and control on a cardiac muscle cell cycle by inhibiting LRP6, and finally promotes repair of cardiac muscle cells and inhibits apoptosis. According to the invention, by exploring the function of inhibiting LRP6 protein of a small molecule drug, a powerful repair reaction is guided after myocardial ischemia reperfusion, so that effective treatment of myocardial infarction is realized. Therefore, finding of an LRP6 inhibitor not only has a potential curative effect on promoting myocardial cells to enter a cell cycle, but also has important significance on treatment of MI.

The invention relates to application of piRNA-AB352916 and a mimetic thereof in preparation of a medicine for treating ischemic heart disease, and belongs to the technical field of medicines. In order to solve the problem that a medicine capable of promoting myocardial cell proliferation and inhibiting myocardial cell apoptosis is lacked in the treatment process of the ischemic heart disease, the invention provides application of piRNA-AB352916 and a mimetic thereof in preparation of a medicine for treating the ischemic heart disease. According to the application disclosed by the invention, the expression level of the piRNA-AB352916 in myocardial regeneration model tissues after cardiac apex resection is obviously increased, and animal experiments prove that the myocardial specific overexpression piRNA-AB352916 not only can promote myocardial cell proliferation, but also can inhibit myocardial cell apoptosis, so that the myocardial infarction area is reduced, and the cardiac function of an infarction mouse is improved. The invention proves that the piRNA-AB352916 and the analogue thereof have prevention and treatment values on the ischemic heart disease.

The invention discloses application of 9 ''-salvianolic acid B monomethyl ester in preparation of a medicine for treating ischemic heart disease, and belongs to the technical field of biological medicine. The CAS number of the 9 ''-salvianolic acid B monomethyl ester is 1167424-31-8, the ischemic heart disease refers to myocardial injury induced by heart ischemia reperfusion, and the invention further provides a pharmaceutical composition or a small molecule injection preparation. Animal experiments show that 9 ''-salvianolic acid B monomethyl ester is exogenously injected to relieve myocardial injury of a mouse and improve the heart function of the mouse, and it is proved that the medicine containing 9''-salvianolic acid B monomethyl ester can improve the ischemic heart disease, especially myocardial injury caused by heart ischemia reperfusion, and has a good application prospect. The invention provides potential drug selection and research direction for preventing and treating ischemic heart disease, and has important clinical application value.

The invention provides a phenylacrylamide compound and a preparation method and application thereof, the phenylacrylamide compound has a structure as shown in a formula I. The phenylacrylamide compound provided by the invention can be well combined with a plurality of target proteins, especially has good inhibitory activity on ACAT1 and 3-KAT targets, and can be used for preparing a medicine for treating cancer. Moreover, the compound has better bioavailability, and can be used for preparing drugs for preventing or treating tumors, cancer pain, radiotherapy and chemotherapy injury, autoimmune diseases, infection and drug-induced myocarditis, cytokine storm, ischemic heart disease, inflammatory diseases and neurodegenerative diseases or anti-aging drugs.

The invention discloses an application of a traditional Chinese medicine monomer hypericin in preparation of related medicines for improving mitochondrial energy metabolism disorder and controlling oxidative stress to prevent and treat ischemic heart disease. The invention provides an application of hypericin in preparation of a product for improving mitochondrial energy metabolism disorder. The mitochondrial energy metabolism disorder is caused by myocardial ischemia reperfusion injury. Researches show that the hypericin regulates energy metabolism and oxidative stress of mitochondria by up-regulating / activating an AMPK / PGC-1alpha signal channel, so that myocardial cell apoptosis is relieved, and finally the protection effect on myocardial ischemia-reperfusion injury is achieved. The invention provides a new thought and a new method for treating MIRI by traditional Chinese medicines.

The present invention provides, in part, a novel small molecule PHD inhibitor having a structure according to Formula (A) or a sub-formula thereof: or a pharmaceutically acceptable salt thereof. The compounds provided herein are useful in the treatment of diseases, including heart diseases (e.g., ischemic heart disease, congestive heart failure, and valvular heart disease), lung diseases (e.g., acute lung injury, pulmonary arterial hypertension, pulmonary fibrosis, and chronic obstructive pulmonary disease), liver diseases (e.g., acute liver failure and liver fibrosis, and cirrhosis), and kidney diseases (e.g., acute liver failure, liver fibrosis, and cirrhosis). Acute kidney injury and chronic kidney disease).

The present invention discloses a hydrogel and its application in ischemic heart disease, relating to the technical field of myocardial infarction repair. The present invention provides a multifunctional hydrogel with injectability, enabling in-situ injection. This hydrogel combines the comprehensive characteristics of improving the conductivity of the infarcted area, generating oxygen, scavenging ROS, promoting M2 polarization of macrophages, and promoting angiogenesis. Its excellent performance is outstanding in alleviating MI / RI, improving the local microenvironment, and enhancing myocardial repair function, providing a new direction for the treatment of heart injury. At the same time, the CSA-δ hydrogel formed after loading drugs has the ability of drug sustained release, which enables the drugs to be released continuously and stably, thereby prolonging the drug action time.

The present invention provides, in part, novel small molecule inhibitors of PHD, having a structure according to Formula (I), and sub-formulas thereof: Formula (I) or a pharmaceutically acceptable salt thereof. The compounds provided herein can be useful for treatment or prevention of diseases including heart (e.g. ischemic heart disease, congestive heart failure, and valvular heart disease), lung (e.g., lung inflammation, pneumonia, acute lung injury, pulmonary hypertension, pulmonary fibrosis, and chronic obstructive pulmonary disease), respiratory (e.g.,respiratory infection, acute respiratory distress syndrome), liver (e.g. acute liver failure and liver fibrosis and cirrhosis), and kidney (e.g. acute kidney injury and chronic kidney disease) disease, inflammatory bowel disease (IBD), ischemic reperfusion injury (e.g., stroke), retinopathy of prematurity (ROP), bronchopulmonary dysplasia (BPD), and white matter injury (WMI).

The invention discloses application of dicaffeoylglucose in treatment and / or prevention of ischemic heart diseases, belongs to the technical field of biological medicines, and provides application of dicaffeoylglucose or pharmaceutically acceptable salt or ester thereof in preparation of medicines for treatment and / or prevention of ischemic heart diseases. A medicine for treating and / or preventing ischemic heart diseases comprises the dicaffeoylglucose or the pharmaceutically acceptable salt or ester of the dicaffeoylglucose. The invention discloses application of dicaffeoylglucose in preparation of a medicine for promoting heart injury repair and regeneration. A medicine for promoting heart injury repair and regeneration comprises dicaffeoylglucose. A zebra fish heart injury high-throughput screening model is utilized to find that the natural compound dicaffeoylglucose extracted from the root of pseudolargetrifoliolious bugbane has a good effect of promoting heart injury repair, so that a new way is opened up for treating myocardial infarction and other ischemic heart diseases, and the pain of a patient is relieved; the social and economic burden of cardiovascular diseases is reduced.

The invention belongs to the technical field of new application of medicines, and provides application of Zhongwinning in preparation of a medicine for treating ischemic heart disease. In a myocardial ischemia rat model test, Zhongwinning shows that the Zhongwinning can obviously improve the left ventricular ejection fraction and the left ventricular short-axis shortening rate of a myocardial ischemia rat; in addition, the rising and falling rates of the ventricular pressure of the myocardial ischemia rats can be remarkably improved, and it is indicated that Zhongutanin can effectively recover the left ventricular systolic function and can effectively repair myocardial injury caused by myocardial ischemia reperfusion. Therefore, according to the experimental research result of the application, the Zhongwinning has a certain application prospect in treating the ischemic heart disease.

The invention provides application of S100A4 in preparation of a medicine for promoting myocardial cell proliferation. It is found that S100A4 not only can significantly induce proliferation of newborn mouse primary myocardial cells and hiPSC-CMs in vitro, but also can significantly improve the cardiac function after myocardial infarction and relieve ventricular fibrosis through AAV9-mediated cardiac targeting overexpression in vivo, and no obvious systemic toxic or side effect or tumorigenic signs are observed. Therefore, the S100A4 protein and the means of overexpressing the S100A4 can be used for promoting myocardial cell proliferation, so that the S100A4 protein can be used for improving or treating heart injury diseases such as ischemic heart disease and the like.

This application relates to the field of gene transduction technology, specifically disclosing a method and application for modifying mesenchymal stem cells (MSCs) targeting myocardial injury. The method includes: S1, obtaining umbilical cord-derived MSCs; S2, performing surface biomimetic modification on the MSCs; S3, gene editing on the MSCs; and S4, co-incubating the engineered MSCs with enzyme-responsive liposomes loaded with nitric oxide donors. The liposomes are embedded in a gelatin coating on the cell membrane surface through hydrophobic interactions, forming a targeted therapeutic system. This method for modifying MSCs targeting myocardial injury can be used for regenerative therapy and repair of myocardial injury diseases such as myocardial infarction and ischemic heart disease. It comprehensively improves the survival and stress tolerance of cells after implantation and enhances the targeting precision to the damaged site, thereby achieving the advantages of efficient, precise, and highly adaptable myocardial repair.

This invention belongs to the field of novel pharmaceutical applications, providing the application of Zhongwu Ning in the preparation of drugs for treating ischemic heart disease. In rat models of myocardial ischemia, Zhongwu Ning significantly increased the left ventricular ejection fraction and left ventricular fractional shortening rate; it also significantly improved the rate of increase and decrease of intracardiac pressure in rats with myocardial ischemia, indicating that Zhongwu Ning can effectively restore left ventricular systolic function and effectively repair myocardial damage caused by myocardial ischemia-reperfusion. Therefore, based on the experimental research results of this application, Zhongwu Ning has certain application prospects in the treatment of ischemic heart disease.

Disclosed herein is a method for detecting cardiomyopathy and heart failure in a subject, the method involving assaying a sample from the subject for decrease in gene or protein expression of a Obg Like ATPase 1 (OLA1) and / or the presence of a Y254C mutation in OLA1, thereby detecting cardiomyopathy and heart failure in the subject. Also disclosed is a method for treating cardiomyopathy, heart failure, myocardial infarction or heart attack, ischemic heart disease, coronary heart disease and hypertrophic cardiomyopathy in a subject, the method involving administering to the subject an expression vector comprising a nucleic acid sequence encoding wild-type Obg Like ATPase 1 (OLA1) operably linked to an expression control sequence.

Reganoxonin is used in the preparation of a drug for the detection of ischemic heart disease by echocardiography. Echocardiography is selected from one or more of stress echocardiography, myocardial angiography, transthoracic Doppler echocardiography, and two-dimensional speckle tracking echocardiography. Ischemic heart disease is selected from one or more of non-obstructive or obstructive ischemic heart disease. The diagnosis of the patient's disease by administering the drug has good accuracy, sensitivity, specificity, and safety.

The invention discloses an application of a compound in preparation of a medicine for treating cardiovascular diseases, the compound is SP3, and the structural formula is shown in the specification. The compound can obviously reduce the myocardial infarction area and ischemia area after myocardial ischemia reperfusion, has a myocardial protection effect, and particularly has a better effect on ischemic heart disease.

The invention relates to the technical field of medicines, in particular to application of an AKT inhibitor targeting FOXO in preparation of a medicine for promoting myocardial ischemic tissue angiogenesis and application of the AKT inhibitor in preparation of a medicine for treating ischemic heart diseases. In the cell level, the AKT inhibitor Ipatasertib can promote migration and tube formation of the HUVEC, and when the 6 [mu] M of Ipatasertib acts on the HUVEC, the expression of AKT can be significantly reduced, and the phosphorylation level of FOXO3 can be inhibited. In an in-vivo experiment, compared with a model group, a mouse in an Ipatasertib intervention group has the advantages that the left ventricular ejection fraction of an echocardiogram is remarkably increased, the myocardial infarction area is remarkably reduced, and the fluorescence density of an angiogenesis marker CD31 + is remarkably increased, so that the Ipatasertib can promote angiogenesis of a myocardial ischemia region of the mouse with acute myocardial infarction and rescue myocardial injury of the mouse.

The present invention relates to cytoprotective compounds and their uses. The present invention relates to cytoprotective, particularly cardioprotective and renoprotective organic compounds, preferably organic compounds that inhibit substrate phosphorylation caused by G protein-coupled receptor kinase 2 (GRK2, ADRBK1). Preferably, the organic compounds inhibit GRK2-mediated phosphorylation of serine / arginine-rich splicing factor 1 (SRSF1, ASF-1, SF2) and / or photosensory factors for the treatment of hypertension, heart disease, cardiac dysfunction or failure, and heart disease-related conditions such as cardiomyocyte necrosis, ischemic heart disease and / or ischemic heart injury or aging. In addition, the present invention relates to methods for identifying inhibitors of (GRK2)-mediated (SRSF1) and / or photosensory factor phosphorylation.

The present invention relates to inhibitors, and compositions containing inhibitors, and uses of the same in the treatment or prevention of a disease, disorder or condition related to HFrEF, such as an ischaemic heart disease, and / or HFpEF.

The present invention provides, in part, a novel small molecule PHD inhibitor, or a pharmaceutically acceptable salt thereof, having a structure according to Formula (A) and its sub-formula. Compounds provided herein are useful for the treatment of diseases, the diseases include heart diseases (e.g., ischemic heart disease, congestive heart failure and valvular heart disease), lung diseases (e.g., acute lung injury, pulmonary arterial hypertension, pulmonary fibrosis and chronic obstructive pulmonary disease), liver diseases (e.g., acute liver failure and liver fibrosis and cirrhosis), and kidney diseases (e.g., acute kidney injury and chronic kidney disease). # imgabs0 #

The invention discloses an application of ilicin A in preparation of a medicine for preventing and treating ischemic heart disease, and belongs to the technical field of ilicin A. An experiment for improving heart functions of a mouse I / R model by the ilicin A is carried out, and male C57BL / 6 mice (with the age of 6-8 weeks; according to the method, 70 mice (the weight is 20 + / -2g) are bred in a constant-temperature and constant-humidity environment, the illumination / darkness period is 12 hours and lasts for one week, food and water are obtained without limitation, all male mice are randomly grouped as follows: a false operation group (n = 10), an I / R group (n = 15), an ilicin A group (30 and 60 mg / kg) and a captopril group (20 mg / kg), the mice in the ilicin A group and the captopril group are subjected to intragastric administration every day five days before the model is established, and the mice in the captopril group are subjected to intragastric administration every day. And the isopyknic contrast solution is applied to the false operation group and the I / R group.

Ischemic heart disease is a leading cause of death and reduced quality of life worldwide. Although revascularization strategies significantly reduce mortality after acute myocardial infarction (MI), many patients with MI develop chronic heart failure over time. We previously reported that human recombinant ANGPTL4 counteracts ischemia-induced vascular endothelial growth factor signaling and disruption of endothelial cell-cell adhesion, thereby inhibiting vascular permeability. We were able to demonstrate that ANGPTL4 administration before MI resulted in protection of the coronary capillary network, no-reflow syndrome, and reduced infarct size in mice. We also demonstrated that the therapeutic effects observed with ANGPTL4 under ischemic conditions were caused by the FLD fragment, not the CCD fragment (WO 2016 / 110498). To further examine the therapeutic potential of the FLD fragment of ANGPTL4 at the onset of reperfusion, we herein used a porcine model, a clinically relevant model of acute myocardial infarction that can be easily and safely translated into patient treatment. We demonstrated that local (antegrade) delivery of the FLD ANGPTL4 to infarcted porcine hearts can efficiently target the lesion site in a clinically relevant manner. A single administration of the FLD of ANGPTL4 improved cardiac function, infarct size, fibrosis, and adverse remodeling parameters 28 days after MI. Short-term MI experiments, coupled with complementary mouse studies, demonstrated myocardial protection. Thus, a single administration of the FLD of ANGPTL4 can reduce ischemia-reperfusion injury and protect against adverse postischemic cardiac remodeling and subsequent ischemic heart failure.

The present disclosure facilitates the evaluation of wide-band phase gradient information of the heart tissue to assess, e.g., the presence of heart ischemic heart disease. Notably, the present disclosure provides an improved and efficient method to identify and risk stratify coronary stenosis of the heart using a high resolution and wide-band cardiac gradient obtained from the patient. The patient data are derived from the cardiac gradient waveforms across one or more leads, in some embodiments, resulting in high-dimensional data and long cardiac gradient records that exhibit complex nonlinear variability. Space-time analysis, via numeric wavelet operators, is used to study the morphology of the cardiac gradient data as a phase space dataset by extracting dynamical and geometrical properties from the phase space dataset.

The invention discloses an ischemic heart disease risk prediction method based on continuous physical examination data, and belongs to the technical field of biological information. Continuous physical examination data and time interval data of each physical examination are vectorized, and characterization learning is carried out on the continuous physical examination data and the time interval data through a time perception attention mechanism; different attention scores are given to each physical examination, physical examination index data and time interval data of the physical examination index data are fused, then the most significant fusion features are imported into a prediction layer for prediction, a cross entropy loss function is adopted to measure the relation between a prediction value and an actual measurement value, and the method is provided for improving the interpretability of classification. Mendel randomization analysis is used for analyzing the causal relationship between part of physical examination indexes and the ischemic heart disease so as to enhance the reliability of identifying disease risk factors by the model, and compared with a traditional method, the performance of the ischemic heart disease risk prediction model is improved, and the risk prediction accuracy of the ischemic heart disease is improved. And meanwhile, the interpretability of the model is enhanced.

A use of N-lactoyl-phenylalanine (Lac-Phe) in a preparation of a medicament for preventing and / or treating ischemic heart disease is provided. It is the first to demonstrate that Lac-Phe can improve the cardiac function in a mouse model of left anterior descending coronary artery stenosis, promote cardiac angiogenesis, improve the viability of hypoxic cardiomyocytes, and inhibit the expression of inflammatory cytokines in the heart, thereby playing an anti-myocardial ischemic injury role. Therefore, the Lac-Phe can be used to prepare a medicament for treating ischemic heart disease. A novel technical means for the treatment of ischemic heart disease is provided.

The present disclosure is directed to the treatment of ischemic heart disease and clinical conditions associated with ischemic heart disease. A composition containing a monoclonal antibody directed against gastric inhibitory polypeptide is administered. This results in cardioprotective effects against acute myocardial infarction, such as a decrease in circulating triglycerides, total cholesterol, and low-density lipoproteins, and an increase in the ratio of high-density lipoprotein to total cholesterol.

The invention belongs to the technical field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine composition for treating ischemic heart disease and a preparation method and application thereof. The traditional Chinese medicine composition is formed by compatibility of salvia miltiorrhiza and hawthorn, active functional components for protecting cardiac muscle in the salvia miltiorrhiza comprise water-soluble phenolic acids and fat-soluble tanshinone, and active functional components for protecting cardiac muscle in the hawthorn comprise procyanidins, flavonoids and triterpenic acids. Through systematic evaluation and research on the traditional Chinese medicine composition, the functional components for treating the IHD are screened out, the action mechanism of the functional components is clarified, and a new thought can be provided for precise treatment of the IHD.

The present invention discloses the application of a small molecule compound in ischemic heart disease, relating to the technical field of the treatment of ischemic heart disease. The CBX7 inhibitor is δ-Amyrenone. δ-Amyrenone can act as an inhibitor of the CBX7 protein, thereby regulating the cell cycle, inhibiting cell apoptosis, and promoting cardiomyocyte proliferation, and has good application prospects in the prevention and / or treatment of ischemic heart disease.